The Effect of Once-Weekly 70 Mg Alendronate Versus Once-Daily 10 Mg Alendronate in the Treatment of Postmenopausal Osteoporosis
Journal Title: Türkiye Osteoporoz Dünyasından - Year 2004, Vol 10, Issue 1
Abstract
The aim of this study was to compare the effect of once-weekly 70 mg alendronate versus once-daily 10 mg alendronate in the treatment of postmenopausal osteoporosis. Sixty-three women with postmenopausal osteoporosis were randomly assigned to two groups. The first group consisting of 26 patients received once-weekly 70 mg alendronate. Thirty-seven patients in the second group were treated with once-daily 10 mg alendronate. All received a daily supplement of 1000 mg calcium. Both treatment regimens were applied for 12 months. The effect of alendronate on bone mineral density (BMD) was investigated by dual energy x-ray absorbtiometry. Serum ALP, Ca and P levels and 24 hours urinary Ca excretion were assessed before the treatment and at the end of 12 months. Serum ALP levels decreased mildly, but in a statistically significant manner in both groups (p<0.05 in group 1, p<0.001 in group 2). There were no significant differences for the other biochemical parameters (p>0.05). At the end of the treatment once-weekly 70 mg alendronate and once-daily 10 mg alendronate produced significant increases in BMD at the lumbar spine (p<0.001), femur neck (Group 1, p<0.05; Group 2, p<0.01 ), trochanteric region (Group 1, p<0.05; Group 2, p<0.001) and at the Ward triangle (p<0.05). There were no significant differences between the groups with regard to side effects (p<0.05). This study indicates that both once-weekly and once-daily alendronate therapy were found to be similarly effective and safe in the treatment of postmenopausal osteoporosis.
Authors and Affiliations
İlker Çorapçı, Cengiz Öner, Onur Armağan, Yavuz Pehlivan, Funda Taşçıoğlu
Keywords
Related Articles
- EP ID EP82979
- DOI -
- Views 107
- Downloads 0
Kienböck’s Disease: Case Report
Osteonecrosis is defined as the death of bone due to interruption of the blood supply to the bone. Kienböck’s disease is osteonecrosis of lunate bone as a result of heavy repetitive loading on wrist. We planned to presen...
Kemik Kaybı Tayininde Osteoporoz Risk Faktörlerinin Değeri
Osteoporoz ciddi ve pahalı bir toplum sağlığı sorunudur. Kemik kaybı riski taşıyan kişilerin ekonomik ve pratik bir yöntemle belirlenmesi önemlidir. Bu çalışmanın amacı kemik kaybı açısından osteoporoz risk faktörlerini...
Depresyonlu Postmenopozal Osteoporozlu Olgularda Kalsitriolün, Kemik Mineral Yoğunluğu, Ağrı ve Yaşam Kalitesi Üzerine Etkisinin Değerlendirilmesi
Bu çalışmanın amacı, postmenopozal osteoporotik kadınlarda depresyonun kemik kaybına olan etkisini ve bu hastalarda kalsitriol tedavisine verilen cevabı araştırmaktır. Bu çalışmaya 72 kadın hasta alınmıştır ( ortalama ya...
Osteoporotik Erkek Hastalarda Vertebral Kırıklar ve Yaşam Kalitesi Arasındaki İlişki
Osteoporoz yaşlı kişilerde en sık görülen metabolik kemik hastalığıdır ve osteoporotik kırıklar morbiditenin majör nedenidir. Vertebral kırıklar ağrı, fiziksel fonksiyon, mobilitede azalma ve günlük yaşam aktivitelerinde...
Tip 1 Diabetes Mellituslu Hastaların Kemik Mineral Yoğunluğu Sağlıklı Kontrollerinkinden Farklı mı?
Amaç: Tip 1 diabetes mellituslu (DM) hastalar ile sağlıklı kontrollerde Kantitatif Ultrasonografi Cihazı (QUS) (Sunlight Omnisense 7000S/8000S) ile ölçülen tibia, radius kemik mineral yoğunluğu(KMY) ve ses hızı [Speed of...